-
公开(公告)号：EP2607348A2
公开(公告)日：2013-06-26
申请号：EP13001154.7
申请日：2010-03-31
IPC分类号： C07C233/81 , A61K31/196 , A61K31/341 , A61K31/381 , A61K31/4025 , A61K31/404 , A61K31/4418 , A61K31/4525 , A61P1/16 , A61P7/02 , A61P9/00 , A61P9/10 , A61P9/14 , A61P11/00 , A61P13/12 , A61P25/00 , A61P25/28 , A61P27/02 , A61P35/00 , A61P35/04
CPC分类号： C07D409/12 , C07C233/81 , C07D213/56 , C07D215/14 , C07D217/16 , C07D295/192 , C07D307/42 , C07D307/54 , C07D307/66 , C07D333/24 , C07D333/36 , C07D405/04 , C07D405/10 , C07D405/12
摘要： The present invention provides an inhibitor of PAI-1 comprising, as an active ingredient, a compound represented by Formula (I) or a salt thereof, or a solvate thereof. The present invention also provides a pharmaceutical composition having an inhibitory action on PAI-1 activity and being efficacious in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity.
摘要翻译： 本发明提供PAI-1的抑制剂，其含有式（I）所示的化合物或其盐或其溶剂化物作为有效成分。 本发明还提供了对PAI-1活性具有抑制作用并且对预防和治疗与PAI-1活性相关的各种疾病有效的药物组合物。
-
2.发明公开
公开(公告)号：EP2272822A1
公开(公告)日：2011-01-12
申请号：EP09729173.6
申请日：2009-03-31
IPC分类号： C07C235/74 , A61K31/167 , A61K31/196 , A61K31/245 , A61K31/34 , A61K31/36 , A61K31/385 , A61K31/40 , A61K31/415 , A61K31/42 , A61K31/421 , A61K31/4409 , A61K31/47 , A61P3/10 , A61P7/02
CPC分类号： C07C235/16 , C07C233/56 , C07C233/88 , C07C235/68 , C07C317/44 , C07C323/60 , C07C2601/14 , C07C2601/20 , C07D207/325 , C07D213/40 , C07D213/74 , C07D215/12 , C07D231/12 , C07D261/08 , C07D263/32 , C07D307/38 , C07D307/79 , C07D317/50 , C07D333/06
摘要： The present invention relates to a novel compound having plasminogen activator inhibitor-1 (PAI-1) inhibitory activity, and a PAI-1 inhibitor comprising the compound as an active ingredient. The present invention further relates to a pharmaceutical composition that has an inhibitory action on PAI-1 activity and is useful in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity. The novel compound is represented by the following general formula.
Each symbol is defined as those in the specification.摘要翻译： 本发明涉及具有纤溶酶原激活物抑制剂-1（PAI-1）抑制活性的新型化合物和包含该化合物作为活性成分的PAI-1抑制剂。 本发明还涉及对PAI-1活性具有抑制作用的药物组合物，并且可用于预防和治疗与PAI-1活性相关的各种疾病。 该新化合物由以下通式表示。 每个符号被定义为说明书中的符号。
-
公开(公告)号：EP2662453A2
公开(公告)日：2013-11-13
申请号：EP13003496.0
申请日：2008-07-31
申请人： TOKAI UNIVERSITY EDUCATIONAL SYSTEM , Tokyo Metropolitan Institute of Medical Science , Renascience CO., LTD. , Medical and Biological Laboratories Co., Ltd.
发明人： Itokawa, Masanari , Miyata, Toshio , Arai, Makoto
IPC分类号： C12Q1/68 , A61K31/415 , A61K31/4152 , A61K31/437 , A61K31/4415 , A61K31/4439 , A61K45/00 , A61P25/18 , C12N15/09 , G01N30/88 , G01N33/15
CPC分类号： C12Q1/527 , A61K31/415 , A61K31/4152 , A61K31/437 , A61K31/4415 , A61K31/4439 , C12Q1/686 , C12Q1/6883 , C12Q2600/106 , C12Q2600/112 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , G01N33/6893 , G01N2333/988
摘要： The present invention relates to a method for diagnosing schizophrenia comprising measuring at least one parameter in a subject, the parameter being selected from the group consisting of (1) a genetic abnormality of glyoxalase I gene, (2) the expression level or activity of glyoxalase I in a biological sample, (3) the amount of a carbonyl-modified protein that is a protein modified with the carbonyl-compound, preferably pentosidine, in a biological sample, and (4) the amount of pyridoxal in a biological sample. The present further relates to a primer, a probe and a reagent for use in said method, as well as an AGE-reader and its use for measuring the amount of carbonyl-modified proteins.
摘要翻译： 本发明涉及一种诊断精神分裂症的方法，包括测量受试者中的至少一个参数，所述参数选自（1）乙二醛酶I基因的遗传异常，（2）乙醛酸酶的表达水平或活性 I在生物样品中，（3）在生物样品中用羰基化合物（优选戊糖）修饰的蛋白质的羰基修饰蛋白质的量，和（4）生物样品中吡哆醛的量。 本发明还涉及用于所述方法的底漆，探针和试剂，以及AGE读数器及其用于测量羰基修饰的蛋白质的量的用途。
-
公开(公告)号：EP2189537B1
公开(公告)日：2014-10-08
申请号：EP08792016.1
申请日：2008-07-31
发明人： ITOKAWA, Masanari , MIYATA, Toshio , ARAI, Makoto
IPC分类号： C12Q1/68 , A61K31/415 , A61K31/4152 , A61K31/437 , A61K31/4415 , A61K31/4439 , A61K45/00 , A61P25/18 , C12N15/09 , G01N30/88 , G01N33/15 , G01N33/50
CPC分类号： C12Q1/527 , A61K31/415 , A61K31/4152 , A61K31/437 , A61K31/4415 , A61K31/4439 , C12Q1/686 , C12Q1/6883 , C12Q2600/106 , C12Q2600/112 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , G01N33/6893 , G01N2333/988
-
公开(公告)号：EP2189537A4
公开(公告)日：2010-08-11
申请号：EP08792016
申请日：2008-07-31
申请人： UNIV TOKAI EDUCATIONAL SYSTEM , TOKYO METROPOLITAN ORG MED RES , RENASCIENCE CO LTD , MEDICAL & BIOL LAB CO LTD
发明人： ITOKAWA MASANARI , MIYATA TOSHIO , ARAI MAKOTO
IPC分类号： C12Q1/68 , A61K31/415 , A61K31/4152 , A61K31/437 , A61K31/4415 , A61K31/4439 , A61K45/00 , A61P25/18 , C12N15/09 , G01N30/88 , G01N33/15 , G01N33/50
CPC分类号： C12Q1/527 , A61K31/415 , A61K31/4152 , A61K31/437 , A61K31/4415 , A61K31/4439 , C12Q1/686 , C12Q1/6883 , C12Q2600/106 , C12Q2600/112 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , G01N33/6893 , G01N2333/988
摘要： The present invention provides a method for diagnosing schizophrenia, and a schizophrenia diagnostic reagent or device for use in the method. The present invention further provides a therapeutic or ameliorating agent for schizophrenia, which is effective for the treatment or amelioration of schizophrenia. The therapeutic or ameliorating agent for schizophrenia contains a carbonyl scavenger or a carbonyl-modified protein formation inhibitor as an active ingredient. The method for diagnosing schizophrenia according to the present invention includes measuring at least one parameter in a subject, the parameter being selected from the group consisting of: (1) a genetic abnormality of glyoxalase I gene; (2) the expression level or activity of glyoxalase I in a biological sample; (3) the amount of a carbonyl compound or a carbonyl-modified protein that is a protein modified with the carbonyl compound; and (4) the amount of pyridoxal in a biological sample.
-
6.发明公开DISEASE MODEL ANIMAL EXPRESSING MEGSIN/RAGE/iNOS AND METHOD OF EVALUATING COMPOUND WITH THE USE OF THE ANIMAL 审中-公开病理模型动物，进行megsin THE / RAGE / iNOS的表达方法评价的化合物使用的各层
公开(公告)号：EP1712125A4
公开(公告)日：2009-06-10
申请号：EP04820285
申请日：2004-12-09
CPC分类号： C07K14/47 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , C12N9/0075 , C12N15/8509 , G01N33/5088 , G01N2800/042 , G01N2800/347
摘要： A triple Tg (megsin/RAGE/iNOS-Tg) is constructed by crossing a megsin-Tg with an RAGE/iNOS-Tg. It is found out that this megsin/RAGE/iNOS-Tg suffers from the onset of remarkable diabetic kidney lesion at an early stage which has never been observed so far and shows various uniform lesion images such as glomerular enlargement. It is also found out that the animal showing these symptoms is useful as a model animal of diabetic nephropathy. That is to say, the disease model animal as described above overexpresses megsin gene, receptor for advanced glycation end product gene and inducible nitric oxide synthase gene and, therefore, suffers from renal dysfunction associated with glomerular disorders at an early stage.
-
7.发明公开
公开(公告)号：EP3623471A1
公开(公告)日：2020-03-18
申请号：EP18797661.8
申请日：2018-05-11
发明人： TATENO, Toshihiro , HIDESAKI, Tomonori , ARAKI, Tadashi , SHINDO, Atsunori , MATSUMOTO, Yoshiko , MIYATA, Toshio , HONJO, Masaru
摘要： Provided are a recombinant microorganism comprising: a gene encoding a pyridoxine oxidase; and a gene encoding a pyridoxamine synthetase having an enzymatic activity of synthesizing pyridoxamine from pyridoxal, in which each of the gene encoding a pyridoxine oxidase and the gene encoding a pyridoxamine synthetase is introduced from outside of a bacterial cell, or is endogenous to the bacterial cell and has an enhanced expression, and a method of producing pyridoxamine or a salt thereof from pyridoxine or a salt thereof using the recombinant microorganism.
-
8.发明授权
公开(公告)号：EP2990057B1
公开(公告)日：2019-03-20
申请号：EP14785000.2
申请日：2014-04-15
发明人： ANDO, Kiyoshi , YAHATA, Takashi , MIYATA, Toshio
IPC分类号： A61K45/06 , A61K45/00 , A61K31/192 , A61K31/196 , A61K31/341 , A61K31/381 , A61K31/40 , A61K31/402 , A61K31/4025 , A61K31/404 , A61K31/4418 , A61K31/445 , A61K31/4525 , A61K31/47 , A61K31/4709 , A61K31/495 , A61K31/506 , A61P7/00 , A61P35/00 , A61P43/00
-
公开(公告)号：EP3424501A1
公开(公告)日：2019-01-09
申请号：EP17760149.9
申请日：2017-03-02
发明人： MIYATA, Toshio , KURE, Shigeo , KURIYAMA, Shinichi , SATO, Hiroki
摘要： The present invention provides a composition effective in improving symptoms of autism spectrum disorder. The composition contains at least one pyridoxamine compound selected from the group consisting of pyridoxamine and pharmaceutically acceptable salts thereof as an active substance. The composition may be used in combination with at least one thiamine compound selected from the group consisting of thiamine, derivatives thereof, and pharmaceutically acceptable salts thereof.
-
公开(公告)号：EP2990057A1
公开(公告)日：2016-03-02
申请号：EP14785000.2
申请日：2014-04-15
发明人： ANDO, Kiyoshi , YAHATA, Takashi , MIYATA, Toshio
CPC分类号： A61K31/341 , A61K31/192 , A61K31/196 , A61K31/381 , A61K31/40 , A61K31/402 , A61K31/4025 , A61K31/404 , A61K31/4418 , A61K31/445 , A61K31/4525 , A61K31/47 , A61K31/4709 , A61K31/495 , A61K31/506 , A61K45/06
摘要： Provided is a novel use of a plasminogen activator inhibitor-1 inhibitor (PAI-1 inhibitor) that is used as an active ingredient of an agent for controlling a tumor stem cell, an agent for enhancing the antitumor effect of an antitumor agent, an agent for tumor chemotherapy, a stem-cell protecting drug, or a hematopoietic disorder improving agent.
摘要翻译： 提供了用作控制肿瘤干细胞的药剂的活性成分的纤溶酶原激活物抑制剂-1抑制剂（PAI-1抑制剂）的新用途，用于增强抗肿瘤剂的抗肿瘤作用的药剂， 用于肿瘤化疗，干细胞保护药物或造血障碍改善剂。
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.025 秒)
